153 related articles for article (PubMed ID: 30906326)
1. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
Diniz MA; Kim S; Tighiouart M
J Probab Stat; 2018; 2018():. PubMed ID: 30906326
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.
Tighiouart M; Li Q; Piantadosi S; Rogatko A
Am J Biostat; 2016; 6(1):1-11. PubMed ID: 28706582
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
Diniz MA; Kim S; Tighiouart M
Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
[TBL] [Abstract][Full Text] [Related]
4. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
7. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
Diniz MA; Quanlin-Li ; Tighiouart M
J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
[TBL] [Abstract][Full Text] [Related]
8. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
[TBL] [Abstract][Full Text] [Related]
9. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
10. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
Wheeler GM; Sweeting MJ; Mander AP
Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
[TBL] [Abstract][Full Text] [Related]
11. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
12. Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
Tighiouart M; Jiménez JL; Diniz MA; Rogatko A
Braz J Biom; 2022 Dec; 40(4):453-468. PubMed ID: 38357386
[TBL] [Abstract][Full Text] [Related]
13. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
Zhang Y; Kutner M; Chen Z
Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
[TBL] [Abstract][Full Text] [Related]
14. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
15. Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
Tighiouart M; Liu Y; Rogatko A
PLoS One; 2014; 9(3):e93070. PubMed ID: 24663812
[TBL] [Abstract][Full Text] [Related]
16. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
Micallef S; Sostelly A; Zhu J; Baverel PG; Mercier F
Contemp Clin Trials Commun; 2022 Apr; 26():100901. PubMed ID: 35198796
[TBL] [Abstract][Full Text] [Related]
17. Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.
Tighiouart M
J R Stat Soc Ser C Appl Stat; 2019 Jan; 68(1):235-250. PubMed ID: 30745708
[TBL] [Abstract][Full Text] [Related]
18. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
19. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
20. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
